Covista Inc. (CVSA)
NYSEConsumer DiscretionaryEducation & Training ServicesSnapshot 2026-10-30
$124.33-3.44%
Close 2026-10-30 · 1-day change
NYSEConsumer DiscretionaryEducation & Training ServicesSnapshot 2026-10-30
Research Workspace
Put CVSA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Consumer Discretionary is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Adjusted EPS at or above $8.05 in FY 2026: Comparison needs review.
View ThesisRevenue growth is slowing — up about 9% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 16%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 37% in its worst 12-month stretch.
View RiskCVSA's case rests on Purpose at Scale: enrollment growth is accelerating revenue growth, backed by cash. Revenue growth rose from 4.5% to 9.7% to 10.7%; Q1 FY2027 adjusted EPS beat consensus by 15.3%. Management raised fiscal 2027 guidance after the beat. CVSA trades at 15× P/E, versus a 15× peer median; expectations look modest versus our view. Our model puts the next-quarter miss probability near 30%. The FY2026 adjusted EPS pillar comparison needs review, so its status remains unverified. Peer multiples imply a price about 41% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. CVSA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering CVSA (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare CVSA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CVSA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Education Services — fair value, gap to price, and forward P/E.
Compare the value case
Put CVSA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Grow enrollment and revenue through Purpose at Scale
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Raised revenue and EPS outlook confirms growth momentum; CFO retirement is a transition to monitor.
Advances: Increase revenue and adjusted EPS guidance for fiscal year 2026
Raised fiscal 2027 outlook after a strong quarter supports growth, though the tracked objective concerns fiscal 2026.
Guidance hike directly supports revenue and EPS growth.